Gut–Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis
Open Access
- 17 June 2026
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 16 (6) , 424
Abstract
Background: The reversal of liver fibrosis is crucial for improving outcomes in chronic liver disease. The gut–liver axis, mediated by the intestinal microbiota, plays a significant role in this process. However, its dynamic changes and mechanisms during reversal remain unclear. This study aimed to systematically reveal these dynamics and explore the link between gut microbiota and metabolism in a spontaneous reversal model. Methods: Intestinal contents were collected from mouse model groups (fibrosis, 4-week reversal, and 12-week reversal). The use of 16S rRNA gene sequencing was employed to analyze gut microbiota structure, and untargeted metabolomics was used to profile metabolic changes. Differential metabolites and microbial taxa were identified using multivariate statistical analysis, followed by pathway enrichment analysis. Spearman correlation analysis was used to construct metabolite–microbiota association networks across different reversal stages. Results: Metabolomic analysis showed significant alterations in multiple pathways during reversal. Linoleic and α-linolenic acid metabolism had a high impact in later stages. Taurine and biotin metabolism remained active throughout. Branched-chain amino acid degradation was enriched later. Microbiota analysis revealed significant structural shifts via beta-diversity. Bacteroidota decreased while Firmicutes increased in 4 weeks. Butyrate-producing families increased, and Akkermansia was enriched later. Integrated analysis demonstrated significant correlations between specific bacteria and metabolites, indicating a close microbiota–metabolism association during reversal. Conclusions: This integrated multi-omics study delineates the potential dynamic reorganization of the gut microbiota and host metabolism during spontaneous liver fibrosis reversal. These findings provide a theoretical basis for understanding the gut–liver axis mechanism in fibrosis reversal and for developing microbiota-targeted intervention strategies.Keywords
This publication has 34 references indexed in Scilit:
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic TargetsProbiotics and Antimicrobial Proteins, 2026
- Effects of dietary soybean phosphatidylethanolamine on intestinal metabolism and microbiota in mice fed low-fat and high-fat dietsFood Research International, 2025
- Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver diseaseEBioMedicine, 2024
- Oral fecal transplantation enriches Lachnospiraceae and butyrate to mitigate acute liver injuryCell Reports, 2023
- Gut-liver axis: Pathophysiological concepts and clinical implicationsCell Metabolism, 2022
- Lysophosphatidylcholine acyltransferase 1 alleviates silica-induced pulmonary fibrosis by modulating lipid metabolismBiomedicine & Pharmacotherapy, 2022
- The role of the gut microbiome and its metabolites in metabolic diseasesProtein & Cell, 2020
- Phospholipid turnover and acyl chain remodeling in the yeast ERBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2020
- Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in MiceHepatology, 2019
- Lipotoxicity and the gut-liver axis in NASH pathogenesisJournal of Hepatology, 2018